Alexander disease: mechanisms, modifiers, and therapeutics
Project Number5P01HD076892-03
Contact PI/Project LeaderMESSING, ALBEE
Awardee OrganizationUNIVERSITY OF WISCONSIN-MADISON
Description
Abstract Text
DESCRIPTION: Alexander disease is a rare and typically fatal neurodegenerative disease of childhood that results from heterozygous mutations in the gene encoding the type III intermediate filament protein GFAP. The pathological signature of the disorder is the Rosenthal fiber, a cytoplasmic inclusion containing intermediate filaments and small heat shock proteins that accumulates in astrocytes throughout the CNS. Prior investigations by our group have let to the acceptance of GFAP mutations as the cause for nearly all cases of Alexander disease, and the rapid translation of this information to clinical practice as the standard for diagnosis. However, the mechanisms by which GFAP mutations cause astrocyte dysfunction and disease remain unclear. The goals of this Program Project are to develop novel model systems of human astrocytes, investigate the impact of mutant GFAP and GFAP excess in astrocytes on neuronal development, viability, and function, and study the pathways by which mis-folded proteins are cleared from the brain. In addition, we will identify and characterize genetic modifiers of disease phenotype and test potential strategies for treatment. Our studies span genetic, biochemical, cellular, physiological, and morphological approaches to these questions, and include model systems ranging from invertebrate through human. The Program will link four laboratories, one using human induced pluripotent stem cells, one using Drosophila, and two using mouse models. An administrative core will coordinate financial reporting, monitor IACUC approvals, and support communication between the groups as well as with the internal and external advisory committees. The Program will promote a focused effort on the role of GFAP in disease, by fostering sharing of reagents, animals, and results among the four labs, through cross-fertilization of ideas, and by regular communication and meetings among laboratory members. These studies promise novel insights into the consequences of GFAP toxicity and the role of astrocytes in brain function and disease. Our hope is that such studies will ultimately lea to strategies for mitigating the devastating effects of astrocyte dysfunction.
Public Health Relevance Statement
PUBLIC HEALTH RELEVANCE: We are studying the role in disease of astrocytes, one of the major cell types in the brain and spinal cord of all vertebrates. We are using the rare disorder, Alexander disease, as a model system in which to address these questions, and to explore novel ways of restoring astrocyte function when it is impaired.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
161202122
UEI
LCLSJAGTNZQ7
Project Start Date
20-September-2014
Project End Date
31-July-2019
Budget Start Date
01-August-2016
Budget End Date
31-July-2017
Project Funding Information for 2016
Total Funding
$1,183,404
Direct Costs
$989,718
Indirect Costs
$193,686
Year
Funding IC
FY Total Cost by IC
2016
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$1,183,404
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01HD076892-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01HD076892-03
Patents
No Patents information available for 5P01HD076892-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01HD076892-03
Clinical Studies
No Clinical Studies information available for 5P01HD076892-03
News and More
Related News Releases
No news release information available for 5P01HD076892-03
History
No Historical information available for 5P01HD076892-03
Similar Projects
No Similar Projects information available for 5P01HD076892-03